Abdellatif Benraiss | Gene Therapy |

Abdellatif Benraiss | Gene Therapy | Best Researcher Award

Dr. Abdellatif Benraiss, Universiy of Rochester, United States

Dr. Abdellatif Benraiss is a distinguished neuroscientist 🧠 specializing in neurobiology, stem cell research 🌱, and gene therapy 🧬. With academic roots in Morocco 🇲🇦 and France 🇫🇷, he earned his Ph.D. in Neurobiology in 1996. His postdoctoral and faculty work in top institutions like Cornell University 🇺🇸 and the University of Rochester has led to pioneering research in Huntington’s disease 🧩, gene transfer therapies 💉, and adult brain regeneration 🧪. He is an esteemed member of several scientific societies 🌍 and a recipient of prestigious awards, including the 2022 Huntington’s Disease Foundation Research Award 🏆.

Publication Profile

Google Scholar

Education

Dr. Abdellatif Benraiss began his academic journey in Morocco 🇲🇦, earning a B.S. in Animal Biology 🐾 from Cadi Ayyad University in 1990. He continued his studies in France 🇫🇷 at Aix-Marseille II University, receiving a second B.S. in Genetics 🧬 in 1991, an M.S. in Neurobiology 🧠 in 1992, and a Ph.D. in Neurobiology in 1996. Pursuing advanced research, he completed a postdoctoral fellowship in Molecular Neurobiology 🔬 at Cornell University Medical College, New York 🇺🇸 (1997–2002), and earned an HDR degree in Gene Therapy 💉 from René Descartes University, Paris, in 2004.

Awards

Dr. Abdellatif Benraiss has been recognized with numerous prestigious honors for his groundbreaking work in neuroscience and gene therapy 🧠💉. In 2022, he received the Huntington’s Disease Foundation Research Award 🧬. He was awarded the NYSTEM Investigator-Initiated Research Project Award in 2011 🧪. His contributions to neurodegenerative disease research earned him the European Leukodystrophy Association (ELA) Award in both 2004 and 2005 🧠🌍. Earlier, in 2003 and 2004, he received fellowships from the French Muscular Dystrophy Association (AFM) 💪🇫🇷. In 2001, he was honored with the Aging Foundation Award from Cornell Medical School 🏛️📜.

Research Focus

Dr. Abdellatif Benraiss’s research focuses on neuroregeneration, gene therapy, and glial cell biology within the context of neurodegenerative diseases 🧠💉. He has pioneered studies on induced neurogenesis in the adult brain, particularly in Huntington’s disease models 🧬, demonstrating how new neurons and glial cells can slow disease progression. His innovative work in gene transfer technologies using viral vectors has contributed to therapies for disorders like metachromatic leukodystrophy and Alzheimer’s disease 🧪. He also explores glial chimerism, aiming to replace diseased brain cells with healthy ones. His multidisciplinary research bridges stem cell therapy, molecular neuroscience, and regenerative medicine 🧫🧍‍♂️.

Publication Top Notes

In vitro neurogenesis by progenitor cells isolated from the adult human hippocampus

Adenoviral brain-derived neurotrophic factor induces both neostriatal and olfactory neuronal recruitment from endogenous progenitor cells in the adult forebrain

SOX9 is an astrocyte-specific nuclear marker in the adult brain outside the neurogenic regions

Nitric oxide negatively regulates mammalian adult neurogenesis

Identification, isolation, and promoter-defined separation of mitotic oligodendrocyte progenitor cells from the adult human subcortical white matter

Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation

Promoter‐targeted selection and isolation of neural progenitor cells from the adult human ventricular zone

Adenovirally expressed noggin and brain-derived neurotrophic factor cooperate to induce new medium spiny neurons from resident progenitor cells in the adult striatal …

Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer’s …

High-yield selection and extraction of two promoter-defined phenotypes of neural stem cells from the fetal human brain

Human glia can both induce and rescue aspects of disease phenotype in Huntington disease

Progenitor cells derived from the adult human subcortical white matter disperse and differentiate as oligodendrocytes within demyelinated lesions of the rat brain

Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease

Neuronal transgene expression in dominant-negative SNARE mice

PDGF-B is required for development of the glymphatic system

Fluorescent Ca2+ indicators directly inhibit the Na,K-ATPase and disrupt cellular functions

Georgina Pamela Coló | Gene Therapy | Best Researcher Award

Georgina Pamela Coló | Gene Therapy | Best Researcher Award

Dr. Georgina Pamela Coló, INIBIBB-CONICET, Argentina

Dr. Georgina Pamela Coló is a distinguished molecular biologist specializing in cancer research. She earned her Ph.D. in Molecular Biology from the University of Buenos Aires (2007, Summa Cum Laude) and holds an MS in Biotechnology from Quilmes National University. Currently a Scientific Researcher at CONICET’s Instituto de Investigaciones Bioquímicas (INIBIBB) in Argentina, she also leads a Max Planck Institute partner group. Her research focuses on cancer progression and therapeutic innovations. With extensive international experience in Germany, Spain, and the U.S., Dr. Coló has authored impactful publications in top-tier journals.

Publication Profile

Scopus

Education

Dr. Georgina Pamela Coló 🎓 is a distinguished molecular biologist with a Ph.D. from the University of Buenos Aires, School of Sciences (2003-2007), where she graduated summa cum laude (10/10) under the mentorship of Dr. M.A. Costas. Prior to her doctorate, she earned an M.S. in Biotechnology (8.74/10) from Quilmes National University (1998-2002). Her academic journey began with a B.Sc. in Science and Technology (1998-2000) and training as a Laboratory Technician 🔬. With a strong foundation in biotechnology and molecular biology, Dr. Coló has made significant contributions to scientific research and innovation. 🧬✨

Experience

Dr. Georgina Pamela Coló 🧬 is a dedicated cancer researcher currently serving as a Scientific Researcher at CONICET (2024-present) at the Instituto de Investigaciones Bioquímicas (INIBIBB), Argentina. She previously worked as an Assistant Researcher (2019-2024) under Dr. Curino. Since 2018, she has led a Max-Planck-Institute partner group 🇩🇪 with Dr. Prof. Reinhard Fässler. Her career includes research fellowships in Spain 🇪🇸 and Germany, as well as postdoctoral studies at INIBIBB, Max-Planck-Institute, and CIB-CSIC. With extensive experience in molecular medicine and cancer biology 🔬, Dr. Coló continues to make groundbreaking contributions to biomedical research. ✨

Awards

Dr. Georgina Pamela Coló 🏆 has received numerous prestigious awards for her outstanding contributions to biomedical research. In 2021, she won the Best Poster Award 🖼️ at the Reunión de Sociedades de Biociencias in Argentina. She was honored with the JCI TOYP Award (2020) for scientific and technological development. In 2019, she received the Lucio Cherny Award for interdisciplinary research 🧬. Her accolades include the Best Poster Award (2018), multiple CONICET fellowships 🎓, and the Max Planck postdoctoral fellowship (2013-2016). Dr. Coló’s impactful research continues to be recognized on both national and international levels.

Research Focus

Dr. Georgina Pamela Coló is a researcher specializing in nanomedicine 🧪, oncology 🎗️, and proteomics 🧬. Her work focuses on amorphous silica nanoparticles and their antitumor activity in triple-negative breast cancer cells 🏥. She also investigates the proteomic effects of hemin in breast cancer, exploring molecular pathways and therapeutic targets. Her research integrates nanotechnology 🏗️ and biochemistry to develop innovative cancer treatments. Through cutting-edge proteomic analysis, she contributes to personalized medicine and targeted drug delivery 🎯. Her studies are highly relevant to pharmaceutical sciences 💊 and biomedical research 🔬, advancing potential cancer therapies.

Publication Top Notes

Amorphous silica nanoparticles exhibit antitumor activity in triple-negative breast cancer cells

Proteomic analysis of the effect of hemin in breast cancer